Fig. 2
From: Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
BET Bromodomain Inhibition increases MHC I Expression in Prostate Cancer. a Representative histograms of HLA-ABC expression on DU145 cells treated with JQ1 and/or IFNγ gated on live cells. b Summary flow cytometry data for A (normalized to DMSO control). n = 1 sample / iteration, repeated × 8. c Representative histograms of HLA-ABC expression in PC3 cells incubated with JQ1 and/or IFNγ gated on live cells. d Summary flow cytometry data for C (normalized to DMSO control). n = 1 sample / iteration, repeated × 8. e HLA-A mRNA levels in DU145. Fold-change normalized to 18 s and then normalized to control (DMSO) treatment. n = 3 / group, repeated × 2. f HLA-B mRNA levels in DU145. Fold-change normalized to 18 s and then normalized to control (DMSO) treatment. n = 3 / group, repeated × 2. g HLA-C mRNA levels in DU145 fold-change normalized to 18 s and then normalized to control (DMSO) treatment. n = 3 / group, repeated × 2. * p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. Error bars = standard deviation